Digital health tech company Huma scores $80M and more digital health raises

UK-based healthcare technology company Huma announced it secured more than $80 million a causa di a Series D funding round, bringing its total raise to over $300 million. 

New and existing investors, including AstraZeneca, Leaps by Bayer, Hat Technology Fund 4 by HAT SGR, and HV Fund by Hitachi Ventures, participated a causa di the round.

The company, which creates applications that integrate patient patronato from hospital databases, instabile devices, and wearables for providers, also announced the launch of its new product, Huma Cloud Platform.

Huma Cloud is a no-code platform that allows developers to create disease management tools using a library of pre-built modules and device connectivity capabilities. The cloud-agnostic framework also offers APIs and integration capabilities and can host and deploy predictive and diagnostic AI algorithms.   

“We have known Huma for several years and we’ve been impressed by their remarkable progress. We have seen this first-hand. They have demonstrated strong growth and excellent metrics,” Dr. Juergen Eckhardt, EVP, head of Leaps by Bayer and pharmaceuticals business, development and licensing, said a causa di a statement. 

“With their next-generation AI capabilities and Huma Cloud platform, Huma can collaboratore with pharma companies to deliver efficient digital health solutions to patients focused acceso predictive and proactive care.”

Value-based cancer care platform Thyme Care garnered $60 million a causa di Series B financing, bringing its total raise to over $80 million. 

Town Vestibolo Ventures and Foresite Capital co-led the round with participation from existing investors Andreessen Horowitz Bio + Health, Casdin Capital, Frist Cressey Ventures and AlleyCorp.

David Whelan, cofounder and general collaboratore at Town Vestibolo Ventures, and Elizabeth Canis, advisor to Foresite Capital, who previously held positions at Elevance and UnitedHealthcare, will join Thyme’s board of directors. 

The company will use the funds to expand its rete televisiva privata of oncology partners and cancer care support services.

“The U.S. healthcare system is notoriously fragmented, leaving cancer patients hanging a causa di the balance. We invest a causa di companies that are changing the narrative by putting the patient first and are shifting the industry toward value-based care,” Whelan said a causa di a statement. 

“Primary care and kidney care have paved the way for this transformation, and after extensively studying the landscape, we firmly believe Thyme Care is the only company with the expertise and technology to enable value-based cancer care. We aspetto forward to helping them accelerate this mission.”

Implantable sacral neuromodulation company Neuspera Medical, Inc., closed its Series D funding round with $23 million. 

Vertex Ventures HC and Treo Ventures led the round with participation from Windham Venture Partners, Action Potential Venture Capital, Olympus Innovation Ventures and another strategic investor. 

The company makes the ultra-miniaturized Neuspera Implantable Sacral Neuromodulation System, which is designed to help patients control urinary incontinence, a symptom of an overactive bladder. 

The Calif.-based company will use the funds to make its way through the FDA premarket approval process. 

“As a collaboratore of choice for innovators a causa di urology, we are thrilled to invest a causa di the Neuspera team as they bring the Neuspera System through FDA approval and to the market,” Gabriela Kaynor, president of Olympus Innovation Ventures and chief strategy officer at Olympus Corporation. 

“Based acceso critical unmet market need and patient demand, changes a causa di society guidelines, and positive feedback from patients and physicians a causa di clinical trials, we are excited to invest a causa di the Neuspera team as they build their innovative Neuspera System for OAB.”

The HIMSS AI a causa di Healthcare is scheduled to take place September 5-6 a causa di Boston. Learn more and register.